Table 4. Cox proportional hazards analysis of melanoma-specific survival among observation patients who remained recurrence-free or received systemic therapy after recurrence, compared with all adjuvant-treated patients.
| Variable | Univariable | Multivariable* | ||
|---|---|---|---|---|
| HR | P value | HR | P value | |
| Adjuvant | ||||
| No | 1 | 0.4598 | 1 | 0.3675 |
| Yes | 0.87 (0.60 to 1.26) | 0.83 (0.55 to 1.25) | ||
| Age (years) at stage III surgery | 1.02 (0.98 to 1.06) | 0.3990 | ||
| Age at stage III surgery | ||||
| ≤85 years | 1 | 0.5965 | 1 | 0.7964 |
| >85 years | 1.16 (0.67 to 2.03) | 0.91 (0.43 to 1.92) | ||
| Sex | ||||
| Female | 1 | 0.6264 | 1 | 0.9222 |
| Male | 1.10 (0.74 to 1.65) | 1.02 (0.66 to 1.60) | ||
| T-stage | ||||
| Non-ulcerated primary | 1 | 0.0030 | 1 | 0.0029 |
| Ulcerated primary | 1.89 (1.24 to 2.88) | 1.97 (1.26 to 3.08) | ||
| N-Stage | ||||
| N1 | 1 | <0.0001 | 1 | 0.0002 |
| N2 | 1.74 (1.11 to 2.71) | 1.81 (1.11 to 2.95) | ||
| N3 | 3.45 (2.21 to 5.38) | 2.85 (1.72 to 4.73) | ||
| Mutation status | ||||
| BRAF/other | 1 | 0.0073 | 1 | 0.0051 |
| Wild type | 0.56 (0.37 to 0.85) | 0.51 (0.31 to 0.82) | ||
*
Multivariable model adjusted for age at stage III surgery, sex, ulceration, AJCC N category and mutation status. Mutation status was available in a subset of patients; those with missing data were excluded from the multivariable model.
AJCC, American Joint Committee on Cancer; NED, no evidence of disease.